Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ensysce Biosciences Inc
(NQ:
ENSC
)
0.5949
+0.0449 (+8.16%)
Streaming Delayed Price
Updated: 3:09 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Ensysce Biosciences Inc
< Previous
1
2
3
Next >
Ensysce Biosciences’ CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge Magazine
April 25, 2024
Via
ACCESSWIRE
Ensysce Biosciences' Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published
April 19, 2024
Via
ACCESSWIRE
Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
April 09, 2024
Via
ACCESSWIRE
Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results
March 15, 2024
Via
ACCESSWIRE
Ensysce Biosciences Receives Positive Nasdaq Listing Determination
February 27, 2024
Via
ACCESSWIRE
Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection
February 21, 2024
Via
ACCESSWIRE
Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript
February 15, 2024
Via
ACCESSWIRE
Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual Conference
February 06, 2024
Via
ACCESSWIRE
Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain
January 31, 2024
Via
ACCESSWIRE
Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds
February 13, 2024
Via
ACCESSWIRE
Ensysce Biosciences to Present Groundbreaking Oral Overdose Protection for Opioids at the 5th Annual NIH HEAL Meeting
January 25, 2024
Via
ACCESSWIRE
Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPAR
January 23, 2024
Via
ACCESSWIRE
Ensysce Biosciences Issues 2024 Shareholder Letter
January 08, 2024
Via
ACCESSWIRE
Ensysce Biosciences Postpones Special Meeting of Stockholders to December 29, 2023
December 19, 2023
Via
ACCESSWIRE
Ensysce Biosciences Announces Key Efficacy Data for Lead Analgesic
December 14, 2023
Via
ACCESSWIRE
Ensysce Biosciences Announces Completion of $1.7 Million Convertible Note Financing
November 29, 2023
Via
ACCESSWIRE
Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-development of BupiZenge(TM) in the United States
November 28, 2023
Via
ACCESSWIRE
Ensysce Biosciences Discusses TAAP and MPAR(R) Applications and OncoZenge Partnership with The Stock Day Podcast
December 11, 2023
Via
ACCESSWIRE
Ensysce Biosciences Announces Enrollment Completion for PF614-201 Clinical Study
November 16, 2023
Via
ACCESSWIRE
Ensysce Biosciences Reports Third Quarter 2023 Financial Results
November 09, 2023
Via
ACCESSWIRE
Ensysce Biosciences Secures $1.7 Million Convertible Note Financing
October 24, 2023
Via
ACCESSWIRE
Ensysce Biosciences Announces Poster Presentation at the AAPS 2023 PharmSci 360
October 18, 2023
Via
ACCESSWIRE
Ensysce Biosciences Releases "Highlights Video" of PAINWeek 2023 Symposium
October 13, 2023
Via
ACCESSWIRE
Ensysce Biosciences to Chair the Fierce New Product Planning Summit 2023
October 03, 2023
Via
ACCESSWIRE
Ensysce Biosciences Announces Completion of Site Initiation Visit for PF614-201 Clinical Study
September 26, 2023
Via
ACCESSWIRE
Ensysce Biosciences to Host Research and Development FAQ Session Following PAINWeek Symposium on September 21, 2023
September 19, 2023
Via
ACCESSWIRE
Ensysce Biosciences Completes Scale Up Manufacture of PF614 to Support Phase 3 Studies
September 14, 2023
Via
ACCESSWIRE
Ensysce Presents "A New Generation of Safer Pain Treatments"
September 07, 2023
Via
ACCESSWIRE
Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023
Via
ACCESSWIRE
Ensysce Biosciences to Present Clinical Dataset at Major PAINWeek Scientific Symposium
August 14, 2023
Via
ACCESSWIRE
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.